Stealth BioTherapeutics Corp. Sponsored ADR (MITO)

Last Closing Price: 0.31 (2022-09-26)

Company Description

Stealth BioTherapeutics Corp is a biopharmaceutical company. It is engaged in developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. The company's product pipeline includes Elamipretide, SBT-20 and SBT-272 which are in clinical stage. Stealth BioTherapeutics Corp is based in Newton, Massachusetts.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $21.09M
Net Income (Most Recent Fiscal Year) $-52.53M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) --
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) --
Return on Assets (Trailing 12 Months) -142.81%
Current Ratio (Most Recent Fiscal Quarter) 3.68
Quick Ratio (Most Recent Fiscal Quarter) 3.68
Debt to Common Equity (Most Recent Fiscal Quarter) --
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $-0.79
Earnings per Share (Most Recent Fiscal Quarter) $-0.12
Earnings per Share (Most Recent Fiscal Year) $-1.06
Diluted Earnings per Share (Trailing 12 Months) $-0.52
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 59.97M
Free Float --
Market Capitalization $18.55M
Average Volume (Last 20 Days) 0.16M
Beta (Past 60 Months) 1.64
Percentage Held By Insiders (Latest Annual Proxy Report) --
Percentage Held By Institutions (Latest 13F Reports) 2.21%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%